PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 863 participants.
Also called NCT04142658
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 863 participants
- Registry
-
NCT04142658
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Terminated
Technical summary
Registry record NCT04142658. Randomized; no masking; primary purpose treatment. Start 2020-05-01 (actual); primary completion 2022-12-12 (actual). Results posted on 2024-03-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban
- Condition
- Aortic Valve Disease
- Condition
- Aortic Valve Stenosis
- Condition
- Aortic Valve Failure
- Intervention (Drug)
- Apixaban 5 MG
- Intervention (Drug)
- Apixaban 2.5 MG
- Intervention (Drug)
- Warfarin
- Intervention (Device)
- On-X Aortic Mechanical Valve
- Lead sponsor
- Artivion Inc.
- Collaborator
- Duke Clinical Research Institute
Record details
- Record id
cardio:ct-nct04142658- Content hash
fc9d2978f3c7aee34712b649ef36a50629f50122049d454affd4a2fdb4880d70